Status:
ACTIVE_NOT_RECRUITING
PRP Injections for Genitourinary Syndrome of Menopause
Lead Sponsor:
Medstar Health Research Institute
Conditions:
PRP
Sexual Function Disturbances
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
Platelet-rich plasma (PRP) is autologous blood which has been centrifuged to separate the supernatant resulting in a solution with high concentration of platelets. Injection of PRP stimulates cell gro...
Eligibility Criteria
Inclusion
- Women (assigned female at birth) at least 18 years old with a clinical diagnosis of GSM
- Sexually active with at least one episode of sexual activity per week in the preceding 4 weeks defined as follows: Partnered or solo penetrative or non-penetrative stimulation of the clitoris or vagina
- English-speaking
- Willingness and able to comply with the study requirements
Exclusion
- Symptomatic pelvic organ prolapse protruding beyond the hymen)
- History of prior vaginal mesh or midurethral mesh sling surgery
- History of pelvic radiation or genital tract malignancy
- Current symptomatic pelvic organ prolapse (stage II or greater)
- Active vulvar dermatoses or genitourinary infection
- Unable to hold anticoagulation
- Hormonal replacement therapy (systemic, local, or vaginal) within 3 months of participation
- Pregnancy or pre-menopausal status
Key Trial Info
Start Date :
March 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 30 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06028009
Start Date
March 1 2024
End Date
April 30 2026
Last Update
November 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MedStar Lafayette Medical Centre
Washington D.C., District of Columbia, United States, 20036